The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISAL 2017 | The utility of measurable residual disease (MRD) assessment in acute myeloid leukemia (AML)
Gert J. Ossenkoppele, MD, PhD of VU University Medical Center, Amsterdam, Netherlands discusses his talk on the utility of measurable residual disease (MRD) assessment in acute myeloid leukemia (AML) presented at the International Symposium on Acute Leukemias (ISAL) 2017 in Munich, Germany. Prof. Ossenkoppele explains that by measuring MRD, it is possible to predict outcome and inform treatment choice; for example, it can help predict which patients will have a relapse. He further discusses the methods to detect MRD, in particular molecular MRD and flow cytometry as well as their advantages and disadvantages.
